Eight developments in bone marrow transplantation

Approximately 14,000 patients in the United States could benefit from a bone marrow transplant each year; however, only four out of every 10 will receive one, according to data from the DKMS organization.

In conjunction with National Marrow Awareness Month, HemOnc Today presents eight recent developments in bone marrow transplantation.

A prolonged course of lenalidomide (Revlimid, Celgene) maintenance following autologous hematopoietic stem cell transplantation improved survival outcomes without increasing the incidence of second primary malignancies in patients with multiple myeloma. Read more.
A pivotal phase 3 study designed to evaluate letermovir (Merck) for the prevention of clinically significant cytomegalovirus infection in high-risk patients who underwent bone marrow transplant met its primary endpoint. Read more.
The FDA granted breakthrough therapy designation to the novel graft modality NiCord (Gamida Cell) for bone marrow transplantation in patients with hematological malignancies. Read more.
Somatic mutations in ASXL1, RUNX1 and TP53 appeared independently associated with poor outcomes and shorter OS in patients undergoing allogeneic HSCT for myelodysplastic syndrome or acute myeloid leukemia. Read more.
Receipt of mogamulizumab (Poteligeo, Kyowa Hakko Kirin) prior to allogeneic HSCT significantly increased risk for graft-versus-host disease (GVHD)–related mortality in adults with T-cell leukemia/lymphoma. Read more.
Patients with pretransplantation minimal residual disease achieved comparable outcomes after receipt of a HSCT from an umbilical cord blood source or HLA–matched unrelated donor. Read more.
Repeated infusions of mesenchymal stromal cells reduced the incidence of chronic GVHD in patients who underwent haploidentical HSCT. Read more.
Cytomegalovirus infection conferred no protective effect against hematologic relapse in patients with leukemia who underwent HSCT. Read more.